Medicamen Biotech Limited · NSE:MEDICAMEQ
Medicamen Biotech — Investor Presentation (June 2020)
16 slides from Medicamen Biotech's investor presentation, June 2020
Slide 1: Investor Presentation June 2020
Investor Presentation June 2020 Committed for affordable quality healthcare and aiming leadership through Medicamen Biotech Limited continual improvement and technology
Slide 2: Safe Harbour Statement
Safe Harbour Statement This document contains certain forward looking statements with respect to the financial condition, results of operations and business of Medicamen Biotech Limited (“MBL”) and certain of the plans and objectives of MBL with respect to these items. By their nature, forward looki
Slide 3: Overview
Overview Business Area ▪ Vertically integrated pharmaceutical company with presence across geographies – India, Latin America, Africa & rest of world (ROW) ▪ Developing, manufacturing and marketing of finished dosages across wide range of therapeutic domains ▪ Strong focus on R&D with over 45 employ
Slide 4: Overall Snapshot - Consolidated
Overall Snapshot - Consolidated Quarterly Revenue and Growth Quarterly PAT margin and Growth % 3,552 3,533 10.5% 10.8% 10.4% 10.6% 3,113 2,778 328 384 368 8.1% 2,352 249 224 Jun'19 Sep'19 Dec'19 Mar'20 Jun'20 Jun'19 Sep'19 Dec'19 Mar'20 Jun'20 Quarterly EBITDA margin and Growth % 606 589 505 17.1% 1
Slide 5: Overall Snapshot - Standalone
Overall Snapshot - Standalone Quarterly Revenue and Growth Quarterly PAT margin and Growth % 3,552 3,533 3,113 10.5% 10.8% 10.4% 2,612 9.5% 328 384 368 8.1% 1,536 210 146 Jun'19 Sep'19 Dec'19 Mar'20 Jun'20 Jun'19 Sep'19 Dec'19 Mar'20 Jun'20 Quarterly EBITDA margin and Growth % 606 589 505 17.1% 17.4
Slide 6: Overall Snapshot (Quarterly) - Consolidated
Overall Snapshot (Quarterly) - Consolidated INR Lacs Q1’FY21 Q4’FY20 Q1’FY20 Revenue from Operations 2,778 2,352 3,113 Other Income 8 110 4 Total Income 2,787 2,462 3,117 COGS 1,836 1,307 2,084 Employee Benefit Expenses 220 247 198 Finance Costs 24 - 16 Depreciation 69 67 57 Other Expenses 314 503 3
Slide 7: Overall Snapshot (Quarterly) - Standalone
Overall Snapshot (Quarterly) - Standalone INR Lacs Q1’FY21 Q4’FY20 Q1’FY20 Revenue from Operations 2,612 1,536 3,113 Other Income 8 107 4 Total Income 2,620 1,643 3,117 COGS 1,695 711 2,084 Employee Benefit Expenses 216 224 198 Finance Costs 24 - 16 Depreciation 69 67 57 Other Expenses 310 440 329 T
Slide 8: Manufacturing facilities of Medicamen Biotech
Manufacturing facilities of Medicamen Biotech Bhiwadi Plant Haridwar Plant (Unit I) Haridwar Plant (Unit II) Location: Rajasthan Location: Uttrakhand Location: Uttrakhand Facility divided into six Facility has a single Dedicated plant to manufacture oncology separate blocks three-storied unit produc
Slide 9: Manufacturing facilities of Medicamen Biotech
Manufacturing facilities of Medicamen Biotech The company initiated commercial production in 1996 Bhiwadi Haridwar Plant Haridwar Plant Plant (Unit I) (Unit II) Covered area: 120,000 square feet Covered area: 32,000 square feet Covered area: 35,000 square General pharmaceutical formulation General p
Slide 10: Global presence
Global presence CIS (Kazakhsthan, South Asia Tajikhstan) Afghanistan etc. India Carribean Island (Cuba, Domino Republic, Curacao, Jamica, Haiti) S.E. Asia (Bhutan, Cambodia, Brazil Philippines) Australia Africa (Nigeria, Ethiopia, Ghana, Zimbabwe, Uganda, Kenya) 10
Slide 11: Oncology Plant at Haridwar Commenced Operations Recently
ONCOLOGY PLANT AT HARIDWAR COMMENCED OPERATIONS RECENTLY 11
Slide 12: Rationale for oncology product selection
Rationale for oncology product selection Products having Substantial 1 global sales more than value US$1b 3 expectation in times to come Easy market entry Therapeutic domain 2 with no IP /Patent hurdle 4 dominance in specific cancer area 12
Slide 13: Robust R&D Capabilities
Robust R&D Capabilities R&D ▪ State-of-art R&D set up duly approved from Department of Scientific and Industrial Chemical Formulation Research (APIs- Research Research (DSIR), Govt of Onco/Non-Onco) India ▪ Development facility at Bhiwadi for development of Active Pharma Ingredients (API) and Interm
Slide 14: Bhiwadi Plant
Bhiwadi Plant 14
Slide 15: New Oncology Plant - Haridwar
New Oncology Plant - Haridwar 15
Slide 16: Thank you!
Thank you! Medicamen Biotech Limited REGISTERED OFFICE 1506, Chiranjiv Tower, 43 Nehru Place, New Delhi - 110019 Phone 011-47589500 (30 Lines) | Fax 011-26213081 | E-mail cs@medicamen.com Website www.medicamen.com
Medicamen Biotech — Investor Presentation (June 2020) on 6ix